StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

Merck m-M-R II (measles, mumps and rubella virus vaccine) — Worldwide sales ($M) ($M)

Form 10-Q / 10-K MD&A Pediatric Vaccines Disclosure (Q4 derived as Full Year − 9M)

Latest, FY2025
480
Period ended Dec 31, 2025
Change on a year earlier
+3.4%
464 in FY2024
History
9 years
Since FY2017
Sources
7
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedM-M-R II (measles, mumps and rubella virus vaccine) — Worldwide sales ($M) ($M)Year on yearSource
FY2025Dec 31, 2025480+3.4%Form 10-K (mrk-20251231.htm, filed 2026-02-24) ↗
FY2024Dec 31, 2024464+7.9%Form 10-K (mrk-20251231.htm, filed 2026-02-24) ↗
FY2023Dec 31, 2023430+4.6%Form 10-K (mrk-20251231.htm, filed 2026-02-24) ↗
FY2022Dec 31, 2022411+5.1%Form 10-K (mrk-20241231.htm, filed 2025-02-25) ↗
FY2021Dec 31, 2021391+3.4%Form 10-K (mrk-20231231.htm, filed 2024-02-26) ↗
FY2020Dec 31, 2020378-31.1%Form 10-K (mrk-20221231.htm, filed 2023-02-24) ↗
FY2019Dec 31, 2019549+27.7%Form 10-K (mrk-20211231.htm, filed 2022-02-25) ↗
FY2018Dec 31, 2018430+12.6%Form 10-K (mrk-20201231.htm, filed 2021-02-25) ↗
FY2017Dec 31, 2017382–Form 10-K (mrk1231201910k.htm, filed 2020-02-26) ↗

Breakdown

What makes up m-m-r ii (measles, mumps and rubella virus vaccine) — worldwide sales ($m)

Cite this data

StockData. (2026). Merck M-M-R II (measles, mumps and rubella virus vaccine) — Worldwide sales ($M) ($M), annual FY2017–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_mmr_ii

See every metric in the Merck KPI table. Data updated Oct 26, 2026.